News | February 19, 2025
Merck’s Welireg receives European approval for two indications
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
WELIREG is the first and only oral hypoxia-inducible factor-2 alpha inhibitor approved in the European Union
Merck has also decided to end the favezelimab clinical development program
The INTerpath-009 clinical trial demonstrates continued expansion of the INTerpath clinical program
At 10 years, more than one-third (34.0%) of patients with advanced melanoma were alive after treatment with KEYTRUDA, compared to 23.6% of patients treated with ipilimumab
Objective response rate of 54.8% seen with Daiichi Sankyo and Merck’s ifinatamab deruxtecan at 12 mg/kg dose in pretreated patients
The companies have initiated Phase 3 studies in patients with high-risk melanoma and non-small cell lung cancer
Data showed that the primary endpoint of recurrence-free survival (RFS) met the pre-specified futility criteria
For the first-line treatment of certain patients with metastatic non-small cell lung cancer
Decision marks the first approval in Europe for an anti-PD-1/L1 therapy in resectable NSCLC based on positive overall survival results
Keynote -564 is the first Phase 3 trial to demonstrate superior overall survival (OS) with adjuvant therapy compared to placebo in patients with RCC
Subscribe To Our Newsletter & Stay Updated
